New York, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of Public Offering (the “Offering”) of approximately $8 million for its client EPWK Holdings Ltd. (NASDAQ: EPWK) (the “Company”), a company that connects businesses with great talents through innovative and efficient cloud-sourcing platforms. The offering is comprised of 24,242,425 unit ...

NYSE American: UEC Proceeds to be Used to Accelerate the Development of the United States Uranium Refining & Conversion Corp CORPUS CHRISTI, Texas , Oct. 3, 2025 /PRNewswire/ - Uranium Energy Corp. (NYSE American: UEC) (the "Company" or "UEC") announced today the pricing of a public offering of 15,500,000 shares of common stock at a price of $13.15 per share (the "Offering"). In connection with the Offering, the Company has granted the underwriter a 30-day option to purchase up to an additional 2,325,000 ...

Not for distribution to U.S. news wire services or dissemination in the United States. VANCOUVER, British Columbia, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Outcrop Silver & Gold Corporation (TSXV:OCG, OTCQX:OCGSF, DE:MRG) (“Outcrop Silver” or the “Company”) is pleased to announce that it has closed its previously announced public offering (the “Offering”) of 65,780,000 units of the Company (the “Units”) at a price of $0.35 per Unit, for aggregate gross proceeds of approximately $23,023,000, including the full exe ...

HONG KONG, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CCSC Technology International Holdings Limited (the “Company”) (Nasdaq: CCTG), a Hong Kong-based company that engages in the sale, design and manufacturing of interconnect products, including connectors, cables and wire harnesses, today announced the closing of its previously announced best-efforts public offering (the “Offering”) of (i) 11,766,627 Class A ordinary shares (the “Class A Ordinary Shares”) and (ii) 23,533,254 warrants to purchase 23,533,254 Class A ...

HONG KONG, Oct. 01, 2025 (GLOBE NEWSWIRE) -- CCSC Technology International Holdings Limited (the “Company”) (Nasdaq: CCTG), a Hong Kong-based company that engages in the sale, design and manufacturing of interconnect products, including connectors, cables and wire harnesses, today announced the pricing of a best-efforts public offering (the “Offering”) of (i) 11,766,627 Class A ordinary shares (the “Class A Ordinary Shares”) and (ii) 23,533,254 warrants to purchase 23,533,254 Class A Ordinary Shares (the “W ...

Accessibility StatementSkip Navigation WOOD DALE, Ill., Sept. 30, 2025 /PRNewswire/ --Â AAR CORP. ("AAR" or the "Company") (NYSE: AIR), a leading provider of aviation services to commercial and government operators, MROs, and OEMs, announced today that it has commenced an underwritten registered public offering of 3,000,000 shares of its common stock. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of the Company's common stock at the ...

SOLANA BEACH, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the pricing of its previously announced underwritten public offering of 441,210 shares of its common stock at a price to the public of $4.40 per share and pre-funded warrants to purchase up to 13,335 shares of ...

Core Viewpoint - Wellgistics Health, Inc. has announced a public offering of shares and associated warrants, indicating a strategic move to raise capital for its operations in pharmaceutical distribution and digital services [1] Company Summary - Wellgistics Health, Inc. is a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment [1] - The company is offering 7,142,862 shares of common stock at a public offering price of $0.70 per share [1] - Along with the shares, the company is also offering warrants to purchase an equal number of shares at the same price of $0.70 per share [1] - The warrants will be exercisable upon issuance and will expire five years thereafter [1] Industry Summary - The announcement reflects ongoing trends in the pharmaceutical distribution industry, particularly the integration of digital solutions and AI technologies [1] - The capital raised through this offering may be utilized to enhance the company's technological capabilities and expand its market presence [1]

Not for distribution to U.S. news wire services or dissemination in the United States. VANCOUVER, British Columbia, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Outcrop Silver & Gold Corporation (TSXV:OCG, OTCQX:OCGSF, DE:MRG) (“Outcrop Silver” or the “Company”) is pleased to announce that it has entered into an agreement with BMO Capital Markets, as sole bookrunner, and Research Capital Corporation, as co-lead agent, on behalf of a syndicate of agents (collectively, the “Agents”), in connection with a best efforts, ...

Core Viewpoint - Jasper Therapeutics, Inc. has announced a public offering of common stock and warrants to raise approximately $30 million to support the development of briquilimab, a novel antibody therapy targeting mast cell driven diseases [1][3]. Group 1: Offering Details - The offering includes 11,670,707 shares of common stock priced at $2.43 per share, along with common warrants to purchase the same number of shares [1]. - Additionally, the offering includes pre-funded warrants for 675,000 shares, priced at $2.43 minus a nominal exercise price of $0.0001 per share [1][2]. - The gross proceeds from the offering are expected to be around $30 million, before deducting underwriting discounts and commissions [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for the advancement of briquilimab's preclinical and clinical development programs, as well as for general corporate purposes, including capital expenditures and working capital [3]. Group 3: Company Overview - Jasper Therapeutics is focused on developing briquilimab as a treatment for chronic mast cell diseases, including chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) [7]. - Briquilimab is a targeted aglycosylated monoclonal antibody that inhibits signaling through the KIT receptor, leading to the depletion of mast cells and addressing the inflammatory response in these diseases [7]. - The company is currently conducting clinical studies demonstrating the efficacy and safety of briquilimab in patients with CSU and CIndU [7].